Last reviewed · How we verify
Cervarix
At a glance
| Generic name | Cervarix |
|---|---|
| Also known as | GSK Biologicals HPV 16/18 VLP/AS04 vaccine, GSK Biologicals' HPV Vaccine GSK580299, GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) vaccine 580299, GSK's commercially available bivalent HPV types 16 and 18 recombinant vaccine containing AS04 adjuvant (Cervarix®), Bivalent HPV vaccine |
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial (PHASE4)
- A Dose Reduction Immunobridging and Safety Study of Two HPV Vaccines in Tanzanian Girls (PHASE3)
- Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO Study (PHASE4)
- Safety and Effects of Using Prime-boost HIVIS DNA and MVA-CMDR Vaccine Regimens With or Without Toll-like Receptor 4 Agonist on HIV Reservoirs in Perinatally HIV Infected Children and Youth (PHASE1)
- Single Dose of Cervarix Vaccine in Girls or Three Doses of Gardasil Vaccine in Women for the Prevention of Human Papillomavirus Infection, the PRIMAVERA-ESCUDDO Trial (PHASE3)
- Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study (PHASE4)
- Normalizing Antibody Detection in First-void Urine
- The KEN SHE Study on HPV-vaccine Efficacy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |